1.Weight gain in children on oxcarbazepine monotherapy.
Garoufi A1, Vartzelis G2, Tsentidis C2, Attilakos A3, Koemtzidou E2, Kossiva L2, Katsarou E4, Soldatou A2. Epilepsy Res. 2016 May;122:110-3. doi: 10.1016/j.eplepsyres.2016.03.004. Epub 2016 Mar 16.
BACKGROUND: Studies of the effect of oxcarbazepine (OXC) on body growth of children with epilepsy are rare and their results are controversial. To the contrary, many studies have shown significant weight gain following valproate (VPA) treatment.
2.Efficacy and acceptability of oxcarbazepine vs. carbamazepine with betahistine mesilate tablets in treating vestibular paroxysmia: a retrospective review.
Yi C1, Wenping X1, Hui X1, Xin H1, Xiue L1, Jun Z1, Shangyong G1. Postgrad Med. 2016 Apr 18:1-4. [Epub ahead of print]
OBJECTIVES: Vestibular paroxysmia (VP) is a rare episodic peripheral vestibular disorder that can cause acute short attacks of vertigo. This study aimed to compare the efficacy and acceptability of carbamazepine (CBZ), CBZ plus betahistine mesilate tablets (BMT) and oxcarbazepine (OXC) plus BMT in treating VP within 12 weeks.
3.Oxcarbazepine-induced liver injury after sensitization by valproic acid: a case report.
Chait Mermelstein A1, Mermelstein J2, Adam T1, Brody BD1, Dubin MJ1. Bipolar Disord. 2016 Apr 4. doi: 10.1111/bdi.12381. [Epub ahead of print]
OBJECTIVE: The aim of the present case report is to describe a potential interaction between valproic acid and oxcarbazepine that resulted in hepatic injury.
4.Effective Treatment of Paroxysmal Nonkinesigenic Dyskinesia With Oxcarbazepine.
Kumar A1, Szekely A, Jabbari B. Clin Neuropharmacol. 2016 Apr 4. [Epub ahead of print]
Paroxysmal nonkinesigenic dyskinesia (PNKD) is a rare chronic disorder characterized by intermittent, non-movement-related involuntary movements. The response to currently available therapies is inconsistent and temporary. We describe here a patient with infantile-onset PNKD who failed a number of pharmaceutical agents used alone or in combination. Treatment with oxcarbazepine resulted in a substantial reduction in the frequency and severity of episodes. The patient has been followed for 4 years now, and the outcome of treatment is consistently favorable. Oxcarbazepine has been effective in managing the kinesigenic form of this disorder; however, its use has never been reported in PNKD to our knowledge. Oxcarbazepine is safer and better tolerated than most of the drugs currently used for treating PNKD, but blinded clinical trials are needed to verify its efficacy in the management of this debilitating, often difficult-to-treat disease.